medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2021-19-41-48medalphabet-2131Research ArticleСтатьиМаммографическая плотность – маркер повышенного риска развития рака молочной железыMammographic density as marker of increased risk of breast cancerhttps://orcid.org/0000-0003-1500-4381ЛабазановаП. Г.LabazanovaP. G.

Лабазанова Патимат Гаджимурадовна, член Российской ассоциации маммологов, член Российского общества рентгенологов и радиологов, член Европейской ассоциации радиологов, м. н. с. Национального центра онкологии репродуктивных органов

Москва

Labazanova Patimat G., member of the Russian Association of Mammologists, member of the Russian Society of Radiologists and Radiologists, member of the European Association of Radiologists, junior researcher of National Centre for Oncology of Reproductive Organs

Moscow

patika92@mail.ruhttps://orcid.org/0000-0001-7109-2174БудановаМ. В.BudanovaM. V.

Буданова Марья Владиславовна, член Российской ассоциации маммологов, член Российского общества рентгенологов и радиологов, член Европейской ассоциации радиологов, врач‑рентгенолог высшей категории Национального центра онкологии репродуктивных органов

Москва

Budanova Marya V., member of the Russian Association of Mammologists, member of the Russian Society of Radiologists and Radiologists, member of the European Association of Radiologists, radiologist of the highest category of the National Centre for Oncology of Reproductive Organs 

Moscow

https://orcid.org/0000-0002-5991-0186БурдинаИ. И.BurdinaI. I.

Бурдина Ирина Игоревна, к. м. н., член Российской ассоциации маммологов, член Российского общества рентгенологов и радиологов, член Европейской ассоциации радиологов, с. н. с. Национального центра онкологии репродуктивных органов

Москва

Burdina Irina I., Ph.D., member of the Russian Association of Mammologists, member of the Russian Society of Radiologists and Radiologists, member of the European Association of Radiologists, senior researcher of National Centre for Oncology of Reproductive Organs

Moscow

https://orcid.org/0000-0001-7154-3326ЗапироваС. Б.ZapirovaS. B.

Запирова Самира Бадрузамановна, к. м. н., член Российской ассоциации маммологов, член Российского общества рентгенологов и радиологов, член Европейской ассоциации радиологов, с. н. с. Национального центра онкологии репродуктивных органов

Москва

Zakirova Samira B., PhD Med, amember of the Russian Association ofMammologists, member of the Russian Society of Radiologists and Radiologists, member of the European Association of Radiologists, senior researcher of National Centre for Oncology of Reproductive Organs

Moscow

https://orcid.org/0000-0002-1313-6420МазоМ. Л.MazoM. L.

Мазо Михаил Львович, к. м. н., ген. секретарь Российской ассоциации маммологов, член Российского общества рентгенологов и радиологов, член Европейской ассоциации радиологов, с. н. с. Национального центра онкологиирепродуктивных органов , доцент кафедры клинической маммологии, лучевой диагностики и лучевой терапии ФПК МР 

Москва

Mazo Mikhail L., PhD Med, general secretary of the Russian Association of Mammologists, member of the Russian Society of Radiologists and Radiologists, member of the European Association of Radiologists, senior researcher of National Centre for Oncology of Reproductive Organs, associate professor at Dept of ClinicalMammology, Radiology and Radiation Therapy

Moscow

https://orcid.org/0000-0002-3495-4895МикушинС. Ю.MikushinS. Yu.

Микушин Сергей Юрьевич, к. м. н., член Российской ассоциациимаммологов, член Российского общества рентгенологов и радиологов, член Европейской ассоциации радиологов, н. с. Национального центра онкологии репродуктивных органов

Москва

Mikushin Sergey Y., PhD Med, member of the Russian Association of Mammologists, member of the Russian Society of Radiologists and Radiologists, member of the European Association of Radiologists, researcher of National Centre for Oncology of Reproductive Organs

Moscow

https://orcid.org/0000-0002-0369-5755ПрокопенкоС. П.ProkopenkoS. P.

Прокопенко Сергей Павлович, к. м. н., вице‑президент Российской ассоциации маммологов, член Российского общества рентгенологов и радиологов, член Европейской ассоциации радиологов, зав. отделением комплексной диагностики и интервенционной радиологии в маммологии Национального центра онкологии репродуктивных органов, зав. кафедрой клинической маммологии, лучевой диагностики и лучевой терапии ФПК МР

Москва

Prokopenko Sergey P., PhD Med, vice-president of the Russian Association of Mammologists, member of the Russian Society of Radiologists and Radiologists, member of the European Association of Radiologists, head of Dept of Comprehensive Diagnostics and Interventional Radiology in Mammology of the National Centre for Oncology of Reproductive Organs , head of Dept of Clinical Mammology, Radiation Diagnostics and Radiation Therapy

Moscow

https://orcid.org/0000-0003-0920-1549РожковаН. И.RozhkovaN. I.

Рожкова Надежда Ивановна, д. м. н., проф., заслуженный деятель науки РФ, президент Российской ассоциации маммологов, член Европейской ассоциации радиологов, рук. Национального центра онкологии репродуктивных органов , проф. кафедры клинической маммологии, лучевой диагностики и лучевой терапии ФПК МР

Москва

Rozhkova Nadezhda I., DM Sci, professor, honored scientist of the Russian Federation, President of the Russian Association of Mammologists, member of the European Association of Radiologists, head og National Centre for Oncology of Reproductive Organs , professor at Dept of Clinical Mammology, Radiation Diagnostics and Radiation Therapy

Moscow

Московский научно-исследовательский онкологический институт имени П. А. Герцена – филиал ФГБУ «Национальный медицинский исследовательский радиологический центр» Минздрава РоссииРоссияMoscow Research Institute n.a. P. A. Herzen – a Branch of the National Medical Radiological Research CentreRussian FederationМосковский научно-исследовательский онкологический институт имени П. А. Герцена – филиал ФГБУ «Национальный медицинский исследовательский радиологический центр» Минздрава России; Медицинский институт ФГАОУ ВО «Российский университет дружбы народов»РоссияMoscow Research Institute n.a. P. A. Herzen – a Branch of the National Medical Radiological Research Centre; Peoples’ Friendship University of RussiaRussian Federation202118082021019Диагностика и онкотерапия (2)4148Copyright © Лабазанова П.Г., Буданова М.В., Бурдина И.И., Запирова С.Б., Мазо М.Л., Микушин С.Ю., Прокопенко С.П., Рожкова Н.И., 20212021Лабазанова П.Г., Буданова М.В., Бурдина И.И., Запирова С.Б., Мазо М.Л., Микушин С.Ю., Прокопенко С.П., Рожкова Н.И.Labazanova P.G., Budanova M.V., Burdina I.I., Zapirova S.B., Mazo M.L., Mikushin S.Y., Prokopenko S.P., Rozhkova N.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/2131

«Маммографическая плотность» (МП) – понятие, вошедшее в медицинскую практику с 2017 года как маркер фактора риска рака молочной железы (РМЖ) согласно 1 -й версии международной классификации NCCN 2017 года Breast Cancer Risk Reduction (National Comprehensive Cancer Network). Термин отражает степень выраженности доброкачественной диффузной дисплазии молочной железы у женщин пострепродуктивного возраста. MП определяется соотношением стромальной, эпителиальной и жировой тканей. По данным литературы, у молодых женщин высокая МП ограничивает возможности рентгеновской маммографии, снижая ее эффективность при онкомаммоскрининге, приводя к выявлению запущенных форм РМЖ. У женщин пострепродуктивного периода при высокой MП вероятность возникновения РМЖ выше, чем при низкой МП. В этой связи МП представляет особый интерес для изучения ее роли в онкогенезе. Последние молекулярно-генетические исследования различий высокой и низкой МП объясняют основные биологические причины, по которым женщины пострепродуктивного возраста с плотной структурой молочной железы подвергаются более высокому риску развития РМЖ. Цель: выделить факторы, влияющие на взаимосвязь МП с риском развития РМЖ на основании сравнительного анализа молекулярно-генетических исследований и рентгенологических проявлений МП разной степени выраженности, и выявить факторы, способствующие формированию вариантов MП.

‘Mammographic density’ (MD) is a concept that has entered medical practice since 2017. as a marker of breast cancer risk factor (BC) according to the international classifiation of NCCN. The term reflcts the degree of severity of benign diffuse breast dysplasia in women of post-reproductive age. MD is determined by the ratio of stromal, epithelial, and adipose tissue. According to the literature, in young women, high MD limits the possibilities of X-ray mammography, reducing its effectiveness in oncomammoscreening, leading to the detection of advanced forms of breast cancer. Post-reproductive women with high MD are more likely to develop breast cancer than those with low MD. In this regard, MD is of particular interest for studying its role in oncogenesis. Recent molecular genetic studies of the differences between high and low MD explain the main biological reasons why post-reproductive women with dense breast structure are at a higher risk of developing breast cancer. The aim is to identify the factors that inflence the relationship of MD with the risk of developing breast cancer based on a comparative analysis of molecular genetic studies and radiological manifestations of MD of different severity and to identify the factors that contribute to the formation of MD variants.

маммографическая плотностьрак молочной железыфакторы рискамаркеры рака молочной железыmammographic densitybreast cancerrisk factorsbreast cancer markersReferencesCatsburg C. et al. Insulin, estrogen, inflmmatory markers, and risk of benign proliferative breast disease. Cancer Res 2014; 74 (12): 3248–58. DOI: 10.1158/0008–5472.CAN-13–3514Catsburg C. et al. Insulin, estrogen, inflmmatory markers, and risk of benign proliferative breast disease. Cancer Res 2014; 74 (12): 3248–58. DOI: 10.1158/0008–5472.CAN-13–3514Каприн А. Д., Старинский В. В., Петрова Г. В. Злокачественные новообразования в России в 2018 г. (заболеваемость и смертность), М.: МНИОИ им. П. А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2019, – 250 с.Kaprin A. D., Starinskiy V. V., Petrova G. V. Zlocachestvennye novoobrazovaniya v Rossii v 2018g. (zabolevaaemost I smertnost), M.: MNIOI im. P. A. Gercena – fiial FGBU “NMIC radiologii” Minzdrava Rossii, 2019–250 p].Sprague BL, Gangnon RE, Burt V, Trentham-Dietz A, Hampton JM, Wellman RD, Kerlikowske K, Miglioretti DL: Prevalence of mammographically dense breasts in the United States. J Natl Cancer Inst 2014, 106 (10).Sprague BL, Gangnon RE, Burt V, Trentham-Dietz A, Hampton JM, Wellman RD, Kerlikowske K, Miglioretti DL: Prevalence of mammographically dense breasts in the United States. J Natl Cancer Inst 2014, 106 (10).Colin C, Schott AM. Re: Breast tissue composition and suscepti- bility to breast cancer. J Natl Cancer Inst. 2011; 103 (1): 77.Colin C, Schott AM. Re: Breast tissue composition and suscepti- bility to breast cancer. J Natl Cancer Inst. 2011; 103 (1): 77.Institute of Medicine Committee on New Approaches to Early Detection and Diagnosis of Breast Cancer: The National Academies Collection: Reports funded by National Institutes of Health. In: Saving Women’s Lives: Strategies for Improving Breast Cancer Detection and Diagnosis: A Breast Cancer Research Foundation and Institute of Medicine Symposium. Edited by Herdman R, Norton L. Washington (DC): National Academies Press (US) National Academy of Sciences.; 2005.Institute of Medicine Committee on New Approaches to Early Detection and Diagnosis of Breast Cancer: The National Academies Collection: Reports funded by National Institutes of Health. In: Saving Women’s Lives: Strategies for Improving Breast Cancer Detection and Diagnosis: A Breast Cancer Research Foundation and Institute of Medicine Symposium. Edited by Herdman R, Norton L. Washington (DC): National Academies Press (US) National Academy of Sciences.; 2005.Pettersson A, Graff RE, Ursin G, Santos Silva ID, McCormack V, Baglietto L, Vachon C, Bakker MF, Giles GG, Chia KS, et al. Mammographic density phenotypes and risk of breast cancer: a meta-analysis. J Natl Cancer Inst. 2014, 106 (5).Pettersson A, Graff RE, Ursin G, Santos Silva ID, McCormack V, Baglietto L, Vachon C, Bakker MF, Giles GG, Chia KS, et al. Mammographic density phenotypes and risk of breast cancer: a meta-analysis. J Natl Cancer Inst. 2014, 106 (5).Patterson SK, Roubidoux MA. Update on new technologies in digital mammography. Int J Women’s Health. 2014; 6: 781–8.Patterson SK, Roubidoux MA. Update on new technologies in digital mammography. Int J Women’s Health. 2014; 6: 781–8.Balleyguier C, Ayadi S, Van Nguyen K, Vanel D, Dromain C, Sigal R. BIRADS classifiation in mammography. Eur J Radiol. 2007; 61 (2): 192–4.Balleyguier C, Ayadi S, Van Nguyen K, Vanel D, Dromain C, Sigal R. BIRADS classifiation in mammography. Eur J Radiol. 2007; 61 (2): 192–4.Jeffreys M, Harvey J, Highnam R. Comparing a new volumetric breast density method (Volpara) to cumulus. Edited by Joan Martí, Arnau Oliver, Jordi Freix-enet, and Robert Martí. In: Digital mammography: 2010/2010. Berlin: Springer; 2010. Pp. 408–413.Jeffreys M, Harvey J, Highnam R. Comparing a new volumetric breast density method (Volpara) to cumulus. Edited by Joan Martí, Arnau Oliver, Jordi Freix-enet, and Robert Martí. In: Digital mammography: 2010/2010. Berlin: Springer; 2010. Pp. 408–413.Byng JW, Boyd NF, Fishell E, Jong RA, Yaffe MJ. The quantitative-analysis of mammographic densities. Phys Med Biol. 1994; 39 (10): 1629–38.Byng JW, Boyd NF, Fishell E, Jong RA, Yaffe MJ. The quantitative-analysis of mammographic densities. Phys Med Biol. 1994; 39 (10): 1629–38.Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, Jong RA, Hislop G, Chiarelli A, Minkin S, et al. Mammographic density and the risk and detection of breast cancer. New Engl J Med. 2007; 356 (3): 227–36.Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, Jong RA, Hislop G, Chiarelli A, Minkin S, et al. Mammographic density and the risk and detection of breast cancer. New Engl J Med. 2007; 356 (3): 227–36.Fletcher SW, Elmore JG. Clinical practice. Mammographic screening for breast cancer. New Engl J Med. 2003; 348 (17): 1672–80.Fletcher SW, Elmore JG. Clinical practice. Mammographic screening for breast cancer. New Engl J Med. 2003; 348 (17): 1672–80.Kolb TM, Lichy J, Newhouse JH. Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that inflence them: an analysis of 27,825 patient evaluations. Radiology 2002; 225 (1):165–175Kolb TM, Lichy J, Newhouse JH. Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that inflence them: an analysis of 27,825 patient evaluations. Radiology 2002; 225 (1):165–175Bae MS, Moon WK, Chang JM, Koo HR, Kim WH, Cho N, Yi A, Yun BL, Lee SH, Kim MY, et al. Breast cancer detected with screening US: reasons for nondetection at mammography. Radiology. 2014; 270 (2): 369–77.Bae MS, Moon WK, Chang JM, Koo HR, Kim WH, Cho N, Yi A, Yun BL, Lee SH, Kim MY, et al. Breast cancer detected with screening US: reasons for nondetection at mammography. Radiology. 2014; 270 (2): 369–77.Boyd NF, Dite GS, Stone J, Gunasekara A, English DR, McCredie MR, Giles GG, Tritchler D, Chiarelli A, Yaffe MJ, et al. Heritability of mammographic density, a risk factor for breast cancer. New Engl J Med. 2002; 347 (12): 886–94.Boyd NF, Dite GS, Stone J, Gunasekara A, English DR, McCredie MR, Giles GG, Tritchler D, Chiarelli A, Yaffe MJ, et al. Heritability of mammographic density, a risk factor for breast cancer. New Engl J Med. 2002; 347 (12): 886–94.Wolfe JN. Risk for breast cancer development determined by mammographic parenchymal pattern. Cancer. 1976; 37 (5): 2486–92.Wolfe JN. Risk for breast cancer development determined by mammographic parenchymal pattern. Cancer. 1976; 37 (5): 2486–92.Wolfe JN. Breast patterns as an index of risk for developing breast cancer. AJR Am J Roentgenol. 1976; 126 (6): 1130–7.Wolfe JN. Breast patterns as an index of risk for developing breast cancer. AJR Am J Roentgenol. 1976; 126 (6): 1130–7.Krook PM. Mammographic parenchymal patterns as risk indicators for incident cancer in a screening program: an extended analysis. AJR Am J Roentgenol. 1978; 131 (6): 1031–5.Krook PM. Mammographic parenchymal patterns as risk indicators for incident cancer in a screening program: an extended analysis. AJR Am J Roentgenol. 1978; 131 (6): 1031–5.Egan RL, Mosteller RC. Breast cancer mammography patterns. Cancer. 1977; 40 (5): 2087–90.Egan RL, Mosteller RC. Breast cancer mammography patterns. Cancer. 1977; 40 (5): 2087–90.Threatt B, Norbeck JM, Ullman NS, Kummer R, Roselle P. Association between mammographic parenchymal pattern classifiation and incidence of breast cancer. Cancer. 1980; 45 (10): 2550–6.Threatt B, Norbeck JM, Ullman NS, Kummer R, Roselle P. Association between mammographic parenchymal pattern classifiation and incidence of breast cancer. Cancer. 1980; 45 (10): 2550–6.Egan RL, McSweeney MB. Mammographic parenchymal patterns and risk of breast cancer. Radiology. 1979; 133 (1): 65–70.Egan RL, McSweeney MB. Mammographic parenchymal patterns and risk of breast cancer. Radiology. 1979; 133 (1): 65–70.Moskowitz M, Gartside P, McLaughlin C. Mammographic pat- terns as markers for high-risk benign breast disease and incident cancers. Radiology. 1980; 134 (2): 293–5.Moskowitz M, Gartside P, McLaughlin C. Mammographic pat- terns as markers for high-risk benign breast disease and incident cancers. Radiology. 1980; 134 (2): 293–5.Tabar L, Dean PB. Mammographic parenchymal patterns. Risk indicator for breast cancer? JAMA. 1982; 247 (2): 185–9.Tabar L, Dean PB. Mammographic parenchymal patterns. Risk indicator for breast cancer? JAMA. 1982; 247 (2): 185–9.Witt I, Hansen HS, Brunner S. The risk of developing breast cancer in relation to mammography fidings. Eur J Radiol. 1984; 4 (1): 65–7.Witt I, Hansen HS, Brunner S. The risk of developing breast cancer in relation to mammography fidings. Eur J Radiol. 1984; 4 (1): 65–7.Gravelle IH, Bulstrode JC, Bulbrook RD, Hayward JL, Wang DY. The relation between radiological patterns of the breast and body weight and height. Br J Radiol. 1982; 55 (649): 23–5.Gravelle IH, Bulstrode JC, Bulbrook RD, Hayward JL, Wang DY. The relation between radiological patterns of the breast and body weight and height. Br J Radiol. 1982; 55 (649): 23–5.Thurfjell E, Hsieh CC, Lipworth L, Ekbom A, Adami HO, Trichopoulos D. Breast size and mammographic pattern in relation to breast cancer risk. Eur J Cancer Prev. 1996; 5 (1): 37–41.Thurfjell E, Hsieh CC, Lipworth L, Ekbom A, Adami HO, Trichopoulos D. Breast size and mammographic pattern in relation to breast cancer risk. Eur J Cancer Prev. 1996; 5 (1): 37–41.Ciatto S, Zappa M. A prospective study of the value of mammographic patterns as indicators of breast cancer risk in a screening experience. Eur J Radiol. 1993; 17 (2): 122–5.Ciatto S, Zappa M. A prospective study of the value of mammographic patterns as indicators of breast cancer risk in a screening experience. Eur J Radiol. 1993; 17 (2): 122–5.Kato I, Beinart C, Bleich A, Su S, Kim M, Toniolo PG. A nested case-control study of mammographic patterns, breast volume, and breast cancer (New York City, NY, United States). Cancer Causes Control. 1995; 6 (5): 431–8.Kato I, Beinart C, Bleich A, Su S, Kim M, Toniolo PG. A nested case-control study of mammographic patterns, breast volume, and breast cancer (New York City, NY, United States). Cancer Causes Control. 1995; 6 (5): 431–8.Byrne C, Schairer C, Wolfe J, Parekh N, Salane M, Brinton LA, Hoover R, Haile R. Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst. 1995; 87 (21): 1622–9.Byrne C, Schairer C, Wolfe J, Parekh N, Salane M, Brinton LA, Hoover R, Haile R. Mammographic features and breast cancer risk: effects with time, age, and menopause status. J Natl Cancer Inst. 1995; 87 (21): 1622–9.de Stavola BL, Gravelle IH, Wang DY, Allen DS, Bulbrook RD, Fentiman IS, Hayward JL, Chaudary MC. Relationship of mammographic parenchymal patterns with breast cancer risk factors and risk of breast cancer in a prospective study. Int J Epidemiol. 1990; 19 (2): 247–54.de Stavola BL, Gravelle IH, Wang DY, Allen DS, Bulbrook RD, Fentiman IS, Hayward JL, Chaudary MC. Relationship of mammographic parenchymal patterns with breast cancer risk factors and risk of breast cancer in a prospective study. Int J Epidemiol. 1990; 19 (2): 247–54.Saftlas AF, Wolfe JN, Hoover RN, Brinton LA, Schairer C, Salane M, Szklo M. Mammographic parenchymal patterns as indicators of breast cancer risk. Am J Epidemiol. 1989; 129 (3): 518–26.Saftlas AF, Wolfe JN, Hoover RN, Brinton LA, Schairer C, Salane M, Szklo M. Mammographic parenchymal patterns as indicators of breast cancer risk. Am J Epidemiol. 1989; 129 (3): 518–26.Sala E, Warren R, McCann J, Duffy S, Day N, Luben R. Mam- mographic parenchymal patterns and mode of detection: implications for the breast screening programme. J Med Screen. 1998; 5 (4): 207–12.Sala E, Warren R, McCann J, Duffy S, Day N, Luben R. Mam- mographic parenchymal patterns and mode of detection: implications for the breast screening programme. J Med Screen. 1998; 5 (4): 207–12.Salminen TM, Saarenmaa IE, Heikkila MM, Hakama M. Is a dense mammographic parenchymal pattern a contraindication to hormonal replacement therapy? Acta Oncol (Stockholm, Sweden). 2000; 39 (8): 969–72.Salminen TM, Saarenmaa IE, Heikkila MM, Hakama M. Is a dense mammographic parenchymal pattern a contraindication to hormonal replacement therapy? Acta Oncol (Stockholm, Sweden). 2000; 39 (8): 969–72.Saftlas AF, Hoover RN, Brinton LA, Szklo M, Olson DR, Salane M, Wolfe JN. Mammographic densities and risk of breast cancer. Cancer. 1991; 67 (11): 2833–8.Saftlas AF, Hoover RN, Brinton LA, Szklo M, Olson DR, Salane M, Wolfe JN. Mammographic densities and risk of breast cancer. Cancer. 1991; 67 (11): 2833–8.Boyd NF, Byng JW, Jong RA, Fishell EK, Little LE, Miller AB, Lockwood GA, Tritchler DL, Yaffe MJ. Quantitative classifiation of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst. 1995; 87 (9): 670–5.Boyd NF, Byng JW, Jong RA, Fishell EK, Little LE, Miller AB, Lockwood GA, Tritchler DL, Yaffe MJ. Quantitative classifiation of mammographic densities and breast cancer risk: results from the Canadian National Breast Screening Study. J Natl Cancer Inst. 1995; 87 (9): 670–5.McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomark Prev. 2006; 15 (6): 1159–69.McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomark Prev. 2006; 15 (6): 1159–69.Boyd NF, Martin LJ, Bronskill M, Yaffe MJ, Duric N, Minkin S. Breast tissue composition and susceptibility to breast cancer. J Natl Cancer Inst. 2010; 102(16): 1224–37.Boyd NF, Martin LJ, Bronskill M, Yaffe MJ, Duric N, Minkin S. Breast tissue composition and susceptibility to breast cancer. J Natl Cancer Inst. 2010; 102(16): 1224–37.Ursin G, Lillie EO, Lee E, Cockburn M, Schork NJ, Cozen W, Parisky YR, Hamilton AS, Astrahan MA, Mack T. The relative importance of genetics and environment on mammographic density. Cancer Epidemiol Biomark Prev. 2009; 18 (1): 102–12.Ursin G, Lillie EO, Lee E, Cockburn M, Schork NJ, Cozen W, Parisky YR, Hamilton AS, Astrahan MA, Mack T. The relative importance of genetics and environment on mammographic density. Cancer Epidemiol Biomark Prev. 2009; 18 (1): 102–12.Li T, Sun L, Miller N, Nicklee T, Woo J, Hulse-Smith L, Tsao MS, Khokha R, Martin L, Boyd N. The association of measured breast tissue characteristics with mammographic density and other risk factors for breast cancer. Cancer Epidemiol Biomark Prev. 2005; 14 (2): 343–9.Li T, Sun L, Miller N, Nicklee T, Woo J, Hulse-Smith L, Tsao MS, Khokha R, Martin L, Boyd N. The association of measured breast tissue characteristics with mammographic density and other risk factors for breast cancer. Cancer Epidemiol Biomark Prev. 2005; 14 (2): 343–9.del Carmen MG, Halpern EF, Kopans DB, Moy B, Moore RH, Goss PE, Hughes KS. Mammographic breast density and race. AJR Am J Roentgenol. 2007; 188 (4): 1147–50.del Carmen MG, Halpern EF, Kopans DB, Moy B, Moore RH, Goss PE, Hughes KS. Mammographic breast density and race. AJR Am J Roentgenol. 2007; 188 (4): 1147–50.Heller SL, Hudson S, Wilkinson LS. Breast density across a regional screening population: effects of age, ethnicity and deprivation. Br J Radiol. 1055; 2015 (88): 20150242.Heller SL, Hudson S, Wilkinson LS. Breast density across a regional screening population: effects of age, ethnicity and deprivation. Br J Radiol. 1055; 2015 (88): 20150242.Ursin G, Ma H, Wu AH, Bernstein L, Salane M, Parisky YR, Astrahan M, Siozon CC, Pike MC. Mammographic density and breast cancer in three ethnic groups. Cancer Epidemiol Biomark Prev. 2003; 12 (4): 332–8.Ursin G, Ma H, Wu AH, Bernstein L, Salane M, Parisky YR, Astrahan M, Siozon CC, Pike MC. Mammographic density and breast cancer in three ethnic groups. Cancer Epidemiol Biomark Prev. 2003; 12 (4): 332–8.Castello A, Ascunce N, Salas-Trejo D, Vidal C, Sanchez- Contador C, Santamarina C, Pedraz-Pingarron C, Moreno MP, Perez-Gomez B, Lope V, et al. Association between western and Mediterranean dietary patterns and mammographic density. Obstet Gynecol. 2016; 128 (3): 574–81.Castello A, Ascunce N, Salas-Trejo D, Vidal C, Sanchez- Contador C, Santamarina C, Pedraz-Pingarron C, Moreno MP, Perez-Gomez B, Lope V, et al. Association between western and Mediterranean dietary patterns and mammographic density. Obstet Gynecol. 2016; 128 (3): 574–81.Nagata C, Matsubara T, Fujita H, Nagao Y, Shibuya C, Kashiki Y, Shimizu H. Associations of mammographic density with dietary factors in Japanese women. Cancer Epidemiol Biomark Prev. 2005; 14 (12): 2877–80.Nagata C, Matsubara T, Fujita H, Nagao Y, Shibuya C, Kashiki Y, Shimizu H. Associations of mammographic density with dietary factors in Japanese women. Cancer Epidemiol Biomark Prev. 2005; 14 (12): 2877–80.Quandt Z, Flom JD, Tehranifar P, Reynolds D, Terry MB, McDonald JA. The association of alcohol consumption with mammographic density in a multiethnic urban population. BMC Cancer. 1094; 2015: 15.Quandt Z, Flom JD, Tehranifar P, Reynolds D, Terry MB, McDonald JA. The association of alcohol consumption with mammographic density in a multiethnic urban population. BMC Cancer. 1094; 2015: 15.Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G. Postmenopausal hormone therapy and change in mam- mographic density. J Natl Cancer Inst. 2003; 95 (1): 30–7.Greendale GA, Reboussin BA, Slone S, Wasilauskas C, Pike MC, Ursin G. Postmenopausal hormone therapy and change in mam- mographic density. J Natl Cancer Inst. 2003; 95 (1): 30–7.Titus-Ernstoff L, Tosteson AN, Kasales C, Weiss J, Goodrich M, Hatch EE, Carney PA. Breast cancer risk factors in relation to breast density (United States). Cancer Causes Control. 2006; 17 (10): 1281–90.Titus-Ernstoff L, Tosteson AN, Kasales C, Weiss J, Goodrich M, Hatch EE, Carney PA. Breast cancer risk factors in relation to breast density (United States). Cancer Causes Control. 2006; 17 (10): 1281–90.Chen FP, Cheung YC, Soong YK. Factors that inflence changes in mammographic density with postmenopausal hormone therapy. Taiwan J Obst Gynecol. 2010; 49 (4): 413–8.Chen FP, Cheung YC, Soong YK. Factors that inflence changes in mammographic density with postmenopausal hormone therapy. Taiwan J Obst Gynecol. 2010; 49 (4): 413–8.Cuzick J, Warwick J, Pinney E, Warren RM, Duffy SW. Tamoxifen and breast density in women at increased risk of breast cancer. J Natl Cancer Inst. 2004; 96 (8): 621–8.Cuzick J, Warwick J, Pinney E, Warren RM, Duffy SW. Tamoxifen and breast density in women at increased risk of breast cancer. J Natl Cancer Inst. 2004; 96 (8): 621–8.Cuzick J, Warwick J, Pinney E, Duffy SW, Cawthorn S, Howell A, Forbes JF, Warren RM. Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case–control study. J Natl Cancer Inst. 2011; 103 (9): 744–52.Cuzick J, Warwick J, Pinney E, Duffy SW, Cawthorn S, Howell A, Forbes JF, Warren RM. Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case–control study. J Natl Cancer Inst. 2011; 103 (9): 744–52.Bertrand KA, Tamimi RM, Scott CG, Jensen MR, Pankratz V, Visscher D, Norman A, Couch F, Shepherd J, Fan B, et al. Mammographic density and risk of breast cancer by age and tumor characteristics. Breast Cancer Res BCR. 2013; 15 (6): R 104.Bertrand KA, Tamimi RM, Scott CG, Jensen MR, Pankratz V, Visscher D, Norman A, Couch F, Shepherd J, Fan B, et al. Mammographic density and risk of breast cancer by age and tumor characteristics. Breast Cancer Res BCR. 2013; 15 (6): R 104.Sartor H, Zackrisson S, Elebro K, Hartman L, Borgquist S. Mammographic density in relation to tumor biomarkers, molecular subtypes, and mode of detection in breast cancer. Cancer Causes Control. 2015; 26 (6): 931–9.Sartor H, Zackrisson S, Elebro K, Hartman L, Borgquist S. Mammographic density in relation to tumor biomarkers, molecular subtypes, and mode of detection in breast cancer. Cancer Causes Control. 2015; 26 (6): 931–9.Theocharis AD, Skandalis SS, Neill T, Multhaupt HA, Hubo M, Frey H, Gopal S, Gomes A, Afratis N, Lim HC, et al. Insights into the key roles of proteoglycans in breast cancer biology and translational medicine. Biochim Biophys Acta. 2015; 1855 (2): 276–300.Theocharis AD, Skandalis SS, Neill T, Multhaupt HA, Hubo M, Frey H, Gopal S, Gomes A, Afratis N, Lim HC, et al. Insights into the key roles of proteoglycans in breast cancer biology and translational medicine. Biochim Biophys Acta. 2015; 1855 (2): 276–300.Leygue E, Snell L, Dotzlaw H, Troup S, Hiller-Hitchcock T, Murphy LC, Roughley PJ, Watson PH. Lumican and decorin are differentially expressed in human breast carcinoma. J Pathol. 2000; 192 (3): 313–20.Leygue E, Snell L, Dotzlaw H, Troup S, Hiller-Hitchcock T, Murphy LC, Roughley PJ, Watson PH. Lumican and decorin are differentially expressed in human breast carcinoma. J Pathol. 2000; 192 (3): 313–20.Insua-Rodriguez J, Oskarsson T. The extracellular matrix in breast cancer. Adv Drug Deliv Rev. 2016; 97: 41–55.Insua-Rodriguez J, Oskarsson T. The extracellular matrix in breast cancer. Adv Drug Deliv Rev. 2016; 97: 41–55.Kauppila S, Stenback F, Risteli J, Jukkola A, Risteli L. Aberrant type I and type III collagen gene expression in human breast cancer in vivo. J Pathol. 1998; 186 (3): 262–8.Kauppila S, Stenback F, Risteli J, Jukkola A, Risteli L. Aberrant type I and type III collagen gene expression in human breast cancer in vivo. J Pathol. 1998; 186 (3): 262–8.Carey SP, Martin KE, Reinhart-King CA. Three-dimensional collagen matrix induces a mechanosensitive invasive epithelial phenotype. Sci Rep. 2017; 7: 42088.Carey SP, Martin KE, Reinhart-King CA. Three-dimensional collagen matrix induces a mechanosensitive invasive epithelial phenotype. Sci Rep. 2017; 7: 42088.Alowami S, Troup S, Al-Haddad S, Kirkpatrick I, Watson PH. Mammographic density is related to stroma and stromal proteoglycan expression. Breast Cancer Res. 2003; 5 (5): R 129–35.Alowami S, Troup S, Al-Haddad S, Kirkpatrick I, Watson PH. Mammographic density is related to stroma and stromal proteoglycan expression. Breast Cancer Res. 2003; 5 (5): R 129–35.Cho A, Howell VM, Colvin EK. The extracellular matrix in epithelial ovarian cancer– a piece of a puzzle. Front Oncol. 2015; 5: 245.Cho A, Howell VM, Colvin EK. The extracellular matrix in epithelial ovarian cancer– a piece of a puzzle. Front Oncol. 2015; 5: 245.Fang X, Balgley BM, Wang W, Park DM, Lee CS. Comparison of multidimensional shotgun technologies targeting tissue proteomics. Electrophoresis. 2009; 30 (23):4063–70.Fang X, Balgley BM, Wang W, Park DM, Lee CS. Comparison of multidimensional shotgun technologies targeting tissue proteomics. Electrophoresis. 2009; 30 (23):4063–70.Yang WT, Lewis MT, Hess K, Wong H, Tsimelzon A, Karadag N, Cairo M, Wei C, Meric-Bernstam F, Brown P, et al. Decreased TGFbeta signaling and increased COX2 expression in high risk women with increased mammographic breast density. Breast Cancer Res Treat. 2010; 119 (2):305–14.Yang WT, Lewis MT, Hess K, Wong H, Tsimelzon A, Karadag N, Cairo M, Wei C, Meric-Bernstam F, Brown P, et al. Decreased TGFbeta signaling and increased COX2 expression in high risk women with increased mammographic breast density. Breast Cancer Res Treat. 2010; 119 (2):305–14.Khan QJ, Kimler BF, O’Dea AP, Zalles CM, Sharma P, Fabian CJ. Mammographic density does not correlate with Ki-67 expression or cytomorphology in benign breast cells obtained by random periareolar fie needle aspiration from women at high risk for breast cancer. Breast Cancer Res. 2007; 9 (3): R 35.Khan QJ, Kimler BF, O’Dea AP, Zalles CM, Sharma P, Fabian CJ. Mammographic density does not correlate with Ki-67 expression or cytomorphology in benign breast cells obtained by random periareolar fie needle aspiration from women at high risk for breast cancer. Breast Cancer Res. 2007; 9 (3): R 35.Chew GL, Huo CW, Huang D, Hill P, Cawson J, Frazer H, Hopper JL, Haviv I, Henderson MA, Britt K, et al. Increased COX-2 expression in epithelial and stromal cells of high mammographic density tissues and in a xenograft model of mammographic density. Breast Cancer Res Treat. 2015; 153 (1): 89–99.Chew GL, Huo CW, Huang D, Hill P, Cawson J, Frazer H, Hopper JL, Haviv I, Henderson MA, Britt K, et al. Increased COX-2 expression in epithelial and stromal cells of high mammographic density tissues and in a xenograft model of mammographic density. Breast Cancer Res Treat. 2015; 153 (1): 89–99.Hawes D, Downey S, Pearce CL, Bartow S, Wan P, Pike MC, Wu AH. Dense breast stromal tissue shows greatly increased con- centration of breast epithelium but no increase in its proliferative activity. Breast Cancer Res. 2006; 8 (2): R 24.Hawes D, Downey S, Pearce CL, Bartow S, Wan P, Pike MC, Wu AH. Dense breast stromal tissue shows greatly increased con- centration of breast epithelium but no increase in its proliferative activity. Breast Cancer Res. 2006; 8 (2): R 24.DeFilippis RA, Chang H, Dumont N, Rabban JT, Chen YY, Fontenay GV, Berman HK, Gauthier ML, Zhao J, Hu D, et al. CD 36 repression activates a multicellular stromal program shared by high mammographic density and tumor tissues. Cancer Discov. 2012; 2 (9): 826–39.DeFilippis RA, Chang H, Dumont N, Rabban JT, Chen YY, Fontenay GV, Berman HK, Gauthier ML, Zhao J, Hu D, et al. CD 36 repression activates a multicellular stromal program shared by high mammographic density and tumor tissues. Cancer Discov. 2012; 2 (9): 826–39.DeFilippis RA, Fordyce C, Patten K, Chang H, Zhao J, Fontenay GV, Kerlikowske K, Parvin B, Tlsty TD. Stress signaling from human mammary epithelial cells contributes to phenotypes of mammographic density. Can Res. 2014; 74 (18): 5032–44.DeFilippis RA, Fordyce C, Patten K, Chang H, Zhao J, Fontenay GV, Kerlikowske K, Parvin B, Tlsty TD. Stress signaling from human mammary epithelial cells contributes to phenotypes of mammographic density. Can Res. 2014; 74 (18): 5032–44.Okello J, Kisembo H, Bugeza S, Galukande M. Breast cancer detection using sonography in women with mammographically dense breasts. BMC Med Imaging 2014; 14 (1)Okello J, Kisembo H, Bugeza S, Galukande M. Breast cancer detection using sonography in women with mammographically dense breasts. BMC Med Imaging 2014; 14 (1)Berg WA, Blume JD, Cormack JB, Mendelson EB, Lehrer D, Bohm-Velez M, Pisano ED, Jong RA, Evans WP, Morton MJ, et al. Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. JAMA. 2008; 299 (18): 2151–63.Berg WA, Blume JD, Cormack JB, Mendelson EB, Lehrer D, Bohm-Velez M, Pisano ED, Jong RA, Evans WP, Morton MJ, et al. Combined screening with ultrasound and mammography vs mammography alone in women at elevated risk of breast cancer. JAMA. 2008; 299 (18): 2151–63.Tagliafio A, Tagliafio G, Astengo D, Cavagnetto F, Rosasco R, Rescinito G, Monetti F, Calabrese M. Mammographic density estimation: one-to-one comparison of digital mammography and digital breast tomosynthesis using fully automated software. Eur Radiol. 2012; 22 (6): 1265–70.Tagliafio A, Tagliafio G, Astengo D, Cavagnetto F, Rosasco R, Rescinito G, Monetti F, Calabrese M. Mammographic density estimation: one-to-one comparison of digital mammography and digital breast tomosynthesis using fully automated software. Eur Radiol. 2012; 22 (6): 1265–70.Haas BM, Kalra V, Geisel J, Raghu M, Durand M, Philpotts LE. Comparison of tomosynthesis plus digital mammography and digital mammography alone for breast cancer screening. Radiology. 2013; 269 (3): 694–700.Haas BM, Kalra V, Geisel J, Raghu M, Durand M, Philpotts LE. Comparison of tomosynthesis plus digital mammography and digital mammography alone for breast cancer screening. Radiology. 2013; 269 (3): 694–700.Roy LD, Dillon LM, Zhou R, Moore LJ, Livasy C, El-Khoury JM, Puri R, Mukherjee P. A tumor specifi antibody to aid breast cancer screening in women with dense breast tissue. Genes Cancer. 2017. https://doi.org/10.18632/genesandcancer.134:1–14.Roy LD, Dillon LM, Zhou R, Moore LJ, Livasy C, El-Khoury JM, Puri R, Mukherjee P. A tumor specifi antibody to aid breast cancer screening in women with dense breast tissue. Genes Cancer. 2017. https://doi.org/10.18632/genesandcancer.134:1–14.Nath S, Mukherjee P. MUC 1: a multifaceted oncoprotein with a key role in cancer progression. Trends Mol Med. 2014; 20 (6): 332–42.Nath S, Mukherjee P. MUC 1: a multifaceted oncoprotein with a key role in cancer progression. Trends Mol Med. 2014; 20 (6): 332–42.Roy LD, Zhou R, Dillon L, Moore LJ, Puri R, Marks JR, Lyerly HK, Mukherjee P. A monoclonal antibody with exceptional specifiity across major breast cancer subtypes. In: ASCO San Antonio Breast Cancer Symposium: 2015; San Antonio, Texas; 2015.Roy LD, Zhou R, Dillon L, Moore LJ, Puri R, Marks JR, Lyerly HK, Mukherjee P. A monoclonal antibody with exceptional specifiity across major breast cancer subtypes. In: ASCO San Antonio Breast Cancer Symposium: 2015; San Antonio, Texas; 2015.Is There a National Reporting Standard? [http://densebreast-info. org/is-there-a-federal-law.aspx]. Accessed 13 Feb 2018.Is There a National Reporting Standard? [http://densebreast-info. org/is-there-a-federal-law.aspx]. Accessed 13 Feb 2018.Clinic M: Breast density–the four levels. In. mayoclinic.org: Mayo Clinic (1998–2018).Clinic M: Breast density–the four levels. In. mayoclinic.org: Mayo Clinic (1998–2018).Каприн А. Д., Рожкова Н. И. 100 страниц о многоликости рака молочной железы, М. ГЭОТАР-Медиа, 2020, 125.Kaprin A. D., Rozhkova N. I. 100 pages about the multifaceted nature of breast cancer, M. GEOTAR-Media, 2020, 125.Лабазанова П. Г., Рожкова Н. И. , Бурдина И. И. , Запирова С. Б., Мазо М. Л. , Микушин С. Ю., Прокопенко С. П. , Якобс О. Э. Маммографическая плотность и риск развития рака молочной железы. Взгляд на историю изучения вопроса. REJR 2020; 10 (2): 205–222. DOI: 10.21569/2222–7415–2020–10–2–205–222.Labazanova P. G., Rozhkova N. I., Burdina I. I., Zapirova S. B., Mazo M. L., Mikushin S. Yu., Prokopenko S. P., Jacobs O. E. Mammographic density and breast cancer risk. A look at the history of the study of the issue. REJR 2020; 10 (2): 205–22. DOI:10.21569/2222–7415–2020–10–2–205–222.Муйжнек Е. Л., Киселев В. И., Якобс О. Э., Рожкова Н. И., Каприн А. Д., Бурдина И. И., Запирова С. Б., Лабазанова П. Г., Мазо М. Л., Прокопенко С. П. Фибросклероз и склерозирующий аденоз с микрокальцинатами в молочной железе. Молекулярный патогенез, своевременная диагностика и лечение. Исследование и практика в медицине, 2019, 6 (2), 75–85.Muizhnek E. L., Kiselev V. I., Jacobs O. E., Rozhkova N. I., Kaprin A. D., Burdina I. I., Zapirova S. B., Labazanova P. G., Mazo M L., Prokopenko S. P. Fibrosclerosis and sclerosing adenosis with microcalcifiations in the mammary gland. Molecular pathogenesis, timely diagnosis and treatment. Research and Practice in Medicine, 2019, 6 (2), 75–85.Микушин С. Ю., Рожкова Н. И., Гришкевич В. И., Якобс О. Э., Бурдина И. И., Запирова С. Б., Мазо М. Л., Прокопенко С. П. Оценка диагностической эффективности рентгенологического томосинтеза при заболеваниях молочной железы. REJR 2019; 9 (3): 86–92. DOI: 10.21569/2222–7415–2019–9–3–86–92.Mikushin S. Yu., Rozhkova N. I., Grishkevich V. I., Yakobs O. E., Burdina I. I., Zapirova S. B., Mazo M. L., Prokopenko S. P. Assessment of the diagnostic effiiency of X-ray tomosynthesis in breast diseases. REJR 2019; 9 (3): 86–92. DOI: 10.21569/2222–7415–2019–9–3–86–92.Якобс О. Э., Рожкова Н. И., Каприн А. Д., Бурдина И. И., Запирова С. Б., Мазо Л. М., Прокопенко С. П. Рентгенонегативный непальпируемый рак молочной железы. Возможности современной лучевой диагностики. Онкология. Журнал им. П. А. Герцена. 2019; 8 (3): 153–160. https://doi.org/10.17116/onkolog20198031153Jacobs O. E., Rozhkova N. I., Kaprin A. D., Burdina I. I., Zapirova S. B. , Mazo L. M., Prokopenko S. P. X-ray negative, non-palpable breast cancer. Possibilities of modern radiation diagnostics. Oncology. Journal them. P. A. Herzen. 2019; 8 (3):153–160. https://doi.org/10.17116/onkolog20198031153

The authors declare that there are no conflicts of interest present.